| |
T/HCTZ
|
V/HCTZ
|
Difference* (T/HCTZ – V/HCTZ)
|
|---|
|
Endpoint, mean ± SD
|
Baseline
|
Last day
|
Baseline
|
Last day
|
p value
|
|---|
|
Serum triglyceride (mg/dL)
|
201.7 ± 247
|
211.8 ± 172
|
196.3 ± 151
|
210.5 ± 177
|
0.91
|
|
LDL-C (mg/dL)
|
165.6 ± 35.4
|
169.8 ± 38.1
|
162.8 ± 33.9
|
165.3 ± 36.0
|
0.17
|
|
HDL-C (mg/dL)
|
37.1 ± 6.5
|
36.6 ± 6.3
|
37.6 ± 7.2
|
37.1 ± 7.0
|
0.64
|
|
Total cholesterol (mg/dL)
|
195.7 ± 23.3
|
198.5 ± 21.7
|
194.5 ± 19.8
|
196.3 ± 20.9
|
0.20
|
|
Potassium (mEq/L)
|
4.4 ± 0.4
|
4.5 ± 0.4
|
4.4 ± 0.4
|
4.4 ± 0.4
|
0.03
|
|
Glucose (mg/dL)
|
128.8 ± 44.1
|
138.8 ± 53.1
|
134.1 ± 49.2
|
140.4 ± 55.2
|
0.58
|
|
HbA1c (%)
|
6.5 ± 0.3
|
6.6 ± 0.3
|
6.6 ± 0.3
|
6.7 ± 0.4
|
0.93
|
|
Albumin:creatinine ratio
|
97.6 ± 330
|
65.1 ± 266
|
66.7 ± 239
|
45.1 ± 177
|
0.97
|
- T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ: valsartan 160 mg plus HCTZ 12.5 mg; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycolated haemoglobin.
- *Analysis of change from baseline
